Life Sciences Tools and Services
Company Overview of AltheaDx, Inc.
AltheaDx, Inc. operates as a molecular diagnostics company that specializes in the field of pharmacogenetics in the United States. The company’s algorithm-based bioinformatic platform and pharmacogenetics (PGx) product testing portfolio serve as a tool to assist healthcare providers in identifying optimal drugs for their patients, as well as dosing guidelines based on a patient’s genetic make-up, current prescription regimen, and other key factors. It designs IDgenetix, a PGx testing portfolio that enables healthcare providers to make timely and evidence-based decisions. The company also offers research and development services that provide a start-to-finish suite of tools focused on molecul...
3550 Dunhill Street
San Diego, CA 92121
Founded in 1998
Key Executives for AltheaDx, Inc.
Chief Executive Officer and Director
President, Chief Operating Officer and Director
Co-Founder and Co-Chairperson of the Board
Senior Vice President of Regulatory Affairs & Quality Assurance
Compensation as of Fiscal Year 2015.
AltheaDx, Inc. Key Developments
AltheaDx, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 08:30 AM
Jun 18 15
AltheaDx, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 08:30 AM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Greg Hamilton, Chief Executive Officer and Director.
AltheaDx, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015
Feb 22 15
AltheaDx, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.
Cardiovascular Institute of the South to Adopt AltheaDx's IDgenetix Testing Services
Feb 5 15
AltheaDx announced an agreement with the Cardiovascular Institute of the South (CIS) to implement AltheaDx's IDgenetix testing portfolio within their system. The IDgenetix pharmacogenetic (PGx) testing portfolio enables personalized therapeutic decisions for patients suffering from some of the most prevalent clinical conditions including cardiovascular disease, neuropsychiatric disorders, and pain. The IDgenetix testing portfolio will assist CIS in identifying optimal drugs for their patients as well as dosing guidelines based on a patient's genetic make-up, current prescription regimen and other key factors. IDgenetix is designed to enable healthcare providers to make timely and evidence-based decisions, reduce the overall cost of patient care by reducing adverse events, optimizing patients' overall therapeutic regimen and helping to achieve a faster therapeutic response.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|